Mike Drummond carried out the overall management of the economics section of the review; assisted in the selection, quality assessment and data extraction of previously published economic evaluations; and provided comments on the protocol and final report.
David Epstein assisted in developing the economic model, extracting data and appraising the economic sections of the industry submissions; and was involved in preparing the final
report.
Carol Forbes carried out the overall management of the project from the data extraction stage; assisted with study selection, data extraction and quality assessment; was involved with data analysis and interpretation; and assisted in writing the final report.
Su Golder was the information officer responsible for developing the search strategies and retrieving references; managed the Endnote library and the ordering of papers; was responsible for writing the
literature search sections of the protocol and report; and also provided comments on both the protocol and the final report.
Neil Hawkins held a lead role in developing the economic model, extracting data and appraising the economic sections of the industry submissions, and was involved in preparing the final report. Anita Kainth held a lead role in all stages of the project and was involved in preparing both the protocol and the final report.
Anne Mason was responsible for selecting, for quality assessment and data extraction of previously published economic evaluations and also assisted in producing the protocol and final report.
Catriona McDaid assisted with data extraction and quality assessment; was involved with data analysis and interpretation; and assisted in producing the final report.
Heather McIntosh assisted in all stages of the project; was responsible for assessment of rare, serious and long-term adverse events; and was involved in preparing both the protocol and the final report.
Susan O’Meara carried out overall management of the project during the initial stages up until the extraction of data; assisted in the selection of studies; was involved in preparing the protocol; and provided comments on the final review. Mark Sculpher assisted in developing the
economic model, appraising the economic sections of the industry submissions; and was involved in preparing and commenting on the final report. Jennifer Wilby held a lead role in all stages of the project and was involved in preparing both the protocol and the final report.
137
Acknowledgements
1. Dorland’s pocket medical dictionary. Philadelphia: W. B. Saunders; 2001.
2. WHO Collaboration Centre for International Drug Monitoring. The UMC – the Global Intelligence Network for Benefits and Risks in Medicinal Products. Sweden: Uppsala Monitoring Centre, 2003. URL: http://www.who-umc.org/. Accessed 21 January 2004.
3. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and EEG classification of epileptic seizures. Epilepsia1981;22:489–501. 4. Commission on Classification and Terminology of
the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia1989;30:389–99. 5. Sander JWAS, Shorvon SD. Epidemiology of the
epilepsies. J Neurol Neurosurg Psychiatry1996; 61:433–43.
6. Cockerell OC, Johnson AL, Sander JWAS, Shorvon SD. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia1997;38:31–46.
7. National Statistics Office. Epilepsy prevalence and prescribing patterns in England and Wales. Health Stat Q2002;15:23–30.
8. Cockerell OC, Johnson AL, Sander JWAS, Hart YM, Goodridge DM, Shorvon SD. Mortality from epilepsy: results from a prospective
population-based study. Lancet1994;344:918–21. 9. Hanna NJ, Black M, Sander JW, Smithson H,
Appleton R, Brown S, et al. The national sentinel clinical audit of epilepsy – related death: epilepsy-death in the shadows.Norwich: The Stationery Office, 2002. URL: http://www.sudep.org. Accessed February 2003.
10. Sander JWAS, Hart YM, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general
population. Lancet1990;336:1267–71. 11. Wallace H, Shorvon S, Tallis R. Age specific
incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age- specific fertility rates of women with epilepsy [comment]. Lancet1998;352:1970–3.
12. Clinical Standards Advisory Group. Services for patients with epilepsy. London: HMSO; 1999.
13. Heaney D, MacDonald B, Everitt A, Stevenson S, Leonardi G, Wilkinson P, et al. Socioeconomic variation in incidence of epilepsy: prospective community based study in south-east England. BMJ2002;325:1013–16.
14. Hart Y, Shorvon S. The nature of epilepsy in the general population. I. Characteristics of patients receiving medication for epilepsy. Epilepsy Res 1995;21:43–9.
15. Devinsky O. Patients with refractory seizures. N Engl J Med1999;340:1565–70.
16. Kwan P, Brodie M. Early identification of refractory epilepsy. N Engl J Med2000;342:314–19.
17. Smith D, Baker GA, Jacoby A, Chadwick DW. The contribution of the measurement of seizure severity to quality of life research. Qual Life Res 1995;4:143–58.
18. Brodie MJ, Dichter MA. Established antiepileptic drugs. Seizure1997;6:159–74.
19. Hart Y, Shorvon, SD. The nature of epilepsy in the general population. II. Medical care. Epilepsy Res 1995;21:51–8.
20. Association of British Pharmaceutical Industry. Medicines compendium 2002.London: Datapharm Communications; 2002.
21. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 44th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2002.
22. Battino D, Dukes, G, Perucca E. Anticonvulsants. In: Dukes MNG, Aronson JK, editors. Meyler’s side effects of drugs. 14th ed. Amsterdam: Elsevier Science; 2000.
23. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews.2nd ed. York: NHS CRD, University of York; 2001.
24. Scoville B, White B, Cereghino JJ, Porter RJ. Suitability and efficiency of crossover drug trial designs in epilepsy. In Dam K, Gram L, Penry JK, editors. Advances in epileptology: XIIth Epilepsy International Symposium.New York: Raven Press; 1981. pp. 113–22.
25. Elbourne D, Altman D, Higgins J, Curtin F, Worthington H, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J
Epidemiol2002;31:140–9. 139